Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Mohammed M. Alvi, Rachel E. Nicoletto, Bayan A. Eshmawi, Hyun (Kate) Kim, Christopher R. Cammarata & Clyde M. Ofner$suffix/text()$suffix/text(). (2020) Intracellular trafficking and cytotoxicity of a gelatine–doxorubicin conjugate in two breast cancer cell lines. Journal of Drug Targeting 28:5, pages 487-499.
Read now
Read now
Liang Zhang, Weiping Yang, Xiao Zhu & Changyuan Wei. (2016) p53 inhibits the expression of p125 and the methylation of POLD1 gene promoter by downregulating the Sp1-induced DNMT1 activities in breast cancer. OncoTargets and Therapy 9, pages 1351-1360.
Read now
Read now
Articles from other publishers (9)
Ahmed M. Elshazly, Melanie M. Sinanian, Victoria Neely, Eesha Chakraborty, Muruj A. Alshehri, Michael K. McGrath, Hisashi Harada, Patricia V. Schoenlein & David A. Gewirtz. (2023) BRD4 Inhibition as a Strategy to Prolong the Response to Standard of Care in Estrogen Receptor-Positive Breast Cancer. Cancers 15:16, pages 4066.
Crossref
Crossref
G Radha, S Raghunandhakumar & S Balakumar. (2023) Dual therapeutic 5-fluorouracil and hesperidin loaded chitosan nanocarrier system: Understanding its synergism on anti-cancer activity. Journal of Drug Delivery Science and Technology 80, pages 104184.
Crossref
Crossref
James A. McCubrey, Akshaya K. Meher, Shaw M. Akula, Stephen L. Abrams, Linda S. Steelman, Michelle M. LaHair, Richard A. Franklin, Alberto M. Martelli, Stefano Ratti, Lucio Cocco, Fulvio Barbaro, Przemysław Duda & Agnieszka Gizak. (2022) Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties. Aging 14:8, pages 3365-3386.
Crossref
Crossref
Mohamed A. El-Desouky, Abdelgawad A. Fahmi, Ibrahim Y. Abdelkader & Karima M. Nasraldin. (2020) Anticancer Effect of Amygdalin (Vitamin B-17) on Hepatocellular Carcinoma Cell Line (HepG2) in the Presence and Absence of Zinc. Anti-Cancer Agents in Medicinal Chemistry 20:4, pages 486-494.
Crossref
Crossref
Maiyon Park, Danielle Upton, Melodie Blackmon, Valerie Dixon, Scott Craver, Dawn Neal & Derek Perkins. (2018) Anacardic acid inhibits pancreatic cancer cell growth, and potentiates chemotherapeutic effect by Chmp1A - ATM - p53 signaling pathway. BMC Complementary and Alternative Medicine 18:1.
Crossref
Crossref
David Moulder, Diana Hatoum, Enoch Tay, Yiguang Lin & Eileen McGowan. (2018) The Roles of p53 in Mitochondrial Dynamics and Cancer Metabolism: The Pendulum between Survival and Death in Breast Cancer?. Cancers 10:6, pages 189.
Crossref
Crossref
Xiao-Ling Ma, Xiao-Cui Li, Fu-Ju Tian, Si-Ming Zhang, Xiao-Rui Liu, Yan Zhang, Jian-Xia Fan & Yi Lin. (2017) Effect of the p53–tristetraprolin–stathmin-1 pathway on trophoblasts at maternal–fetal interface. PLOS ONE 12:6, pages e0179852.
Crossref
Crossref
Diana Hatoum, Daniel Yagoub, Alireza Ahadi, Najah T. Nassif & Eileen M. McGowan. (2017) Annexin/S100A Protein Family Regulation through p14ARF-p53 Activation: A Role in Cell Survival and Predicting Treatment Outcomes in Breast Cancer. PLOS ONE 12:1, pages e0169925.
Crossref
Crossref
Chih-Yang Huang, Wei-Wen Kuo, Jeng-Fan Lo, Tsung-Jung Ho, Pei-ying Pai, Shu-Fen Chiang, Pei-Yu Chen, Fu-Jen Tsai, Chang-Hai Tsai & Chih-Yang Huang. (2016) Doxorubicin attenuates CHIP-guarded HSF1 nuclear translocation and protein stability to trigger IGF-IIR-dependent cardiomyocyte death. Cell Death & Disease 7:11, pages e2455-e2455.
Crossref
Crossref